Simple Summary The systemic treatment of advanced sarcoma remains challenging.
Conventional chemotherapy and anti-angiogenic agents, even in the most responsive …

Childhood cancer is considered rare, corresponding to~ 3% of all malignant neoplasms in
the human population. The World Health Organization (WHO) reports a universal …

Simple Summary Although progress has been made in the treatment and survival of patients
with a range of malignancies, the prognosis for patients harboring metastatic osteosarcoma …

Targeted therapies of programmed cell death protein-1 (PD-1) inhibitors and protein
tyrosinase inhibitors (TKIs) have offered new treatment strategies and promoted the …

Simple Summary Dedifferentiated chondrosarcoma is a rare type of cancer that is very
aggressive and has a poor prognosis with poor survival rates. This disease can affect …

Recent studies have shown that MRI demonstrates promising results for evaluating the
chemotherapy efficacy in bone sarcomas. This article reviews current methods for evaluating …

Sarcomas are a group of malignancies of mesenchymal origin with a plethora of subtypes.
Given the sheer heterogeneity of various subtypes and the rarity of the disease, the …

There has been no significant efficacy in treating osteosarcoma (OS) metastasis after nearly
four decades of trials. This motivates us to elucidate OS therapies using their four …

Abstract Mitogen-inducible gene 6 (Mig6) is a tumor suppressor that inactivates oncogenic
kinases by disrupting the dimerization of kinase domain using its segment 1 (SGT1) …

Background/Aim: Lenvatinib, an oral multikinase inhibitor, has demonstrated promising
activity in patients with osteosarcoma (OS). Therefore, it is worth exploring the inhibitory …